[{"orgOrder":0,"company":"Rallybio","sponsor":"Pivotal bioVenture Partners","pharmaFlowCategory":"D","amount":"$145.0 million","upfrontCash":"Undisclosed","newsHeadline":"Rallybio Scores $145M, Unveils Lead Rare Disease Program","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Series B Financing","leadProduct":"RLYB211","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Rallybio","amount2":0.14999999999999999,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.14999999999999999,"dosageForm":"","sponsorNew":"Rallybio \/ Pivotal bioVenture Partners","highestDevelopmentStatusID":"7","companyTruncated":"Rallybio \/ Pivotal bioVenture Partners"},{"orgOrder":0,"company":"Rallybio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rallybio Further Broadens Drug Development Capabilities with Addition of R\u00f3is\u00edn Armstrong, PhD","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"RLYB211","moa":"HPA-1a","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Rallybio","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Rallybio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Rallybio \/ Not Applicable"},{"orgOrder":0,"company":"Rallybio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rallybio Announces First-in-Human Dosing in RLYB211 Phase 1\/2 Study","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"RLYB211","moa":"HPA-1a","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Rallybio","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Rallybio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Rallybio \/ Not Applicable"},{"orgOrder":0,"company":"Rallybio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rallybio Reports Positive Data in Its Clinical Program for the Prevention of Fetal and Neonatal Alloimmune Thrombocytopenia","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"RLYB211","moa":"HPA-1a","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Rallybio","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Rallybio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Rallybio \/ Not Applicable"},{"orgOrder":0,"company":"Rallybio","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$3.0 million","newsHeadline":"Rallybio Announces In-Licensing of Potential First-In-Class Preclinical Antibody Candidate from Sanofi","therapeuticArea":"Hematology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Licensing Agreement","leadProduct":"RLYB331","moa":"Matriptase-2","url1":"","url2":"","graph1":"Hematology","graph2":"Preclinical","graph3":"Rallybio","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Rallybio \/ Rallybio Corporation","highestDevelopmentStatusID":"4","companyTruncated":"Rallybio \/ Rallybio Corporation"},{"orgOrder":0,"company":"Rallybio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rallybio Announces Positive Phase 1 Single Ascending Dose Results for RLYB116, an Innovative Subcutaneously Injected Inhibitor of Complement Component 5","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"RLYB116","moa":"Completent C5","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Rallybio","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Rallybio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Rallybio \/ Not Applicable"},{"orgOrder":0,"company":"Rallybio","sponsor":"AbCellera","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AbCellera and Rallybio Announce Strategic Alliance to Discover, Develop, and Commercialize Novel Antibody-Based Therapeutics for Rare Diseases","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Collaboration","leadProduct":"Antibody-based Therapy","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Discovery Platform","graph3":"Rallybio","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Rallybio \/ Rallybio","highestDevelopmentStatusID":"3","companyTruncated":"Rallybio \/ Rallybio"},{"orgOrder":0,"company":"Rallybio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rallybio Announces Publication of Data Highlighting the Ability of HPA-1a-Specific Antibodies to Prevent Alloimmunization in an Authentic Mouse Model of FNAIT","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"RLYB212","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Rallybio","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Rallybio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Rallybio \/ Not Applicable"},{"orgOrder":0,"company":"Rallybio","sponsor":"EyePoint Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"EyePoint and Rallybio Announce Research Collaboration to Evaluate Rallybio's Inhibitor of Complement Component 5 (C5) and EyePoint's Proprietary Durasert\u00ae Technology for Sustained Intraocular Delivery in Geographic Atrophy","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Collaboration","leadProduct":"RLYB114","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Rallybio","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Rallybio \/ Rallybio","highestDevelopmentStatusID":"4","companyTruncated":"Rallybio \/ Rallybio"},{"orgOrder":0,"company":"Rallybio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rallybio Announces Proof-of-Concept Achieved for RLYB212, a Novel Monoclonal anti-HPA-1a Antibody to Prevent Fetal and Neonatal Alloimmune Thrombocytopenia","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"RLYB212","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Rallybio","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Rallybio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Rallybio \/ Not Applicable"},{"orgOrder":0,"company":"Rallybio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rallybio Announces Clinical Proof-of-Concept Results for RLYB211, an Anti-HPA-1a Polyclonal Antibody for the Prevention of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT), Published in the Journal of Thrombosis and Haemostasis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"RLYB211","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Rallybio","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Rallybio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Rallybio \/ Not Applicable"},{"orgOrder":0,"company":"Rallybio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rallybio Announces Proof-of-Concept Results and Development Updates for RLYB212, a Novel Monoclonal anti-HPA-1a Antibody to Prevent Fetal and Neonatal Alloimmune Thrombocytopenia","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"RLYB212","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Rallybio","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Rallybio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Rallybio \/ Not Applicable"},{"orgOrder":0,"company":"Rallybio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rallybio Announces Preliminary Phase 1 Multiple Ascending Dose Data for RLYB116, an Innovative Subcutaneously Injected Inhibitor of Complement Component 5","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"RLYB116","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Rallybio","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Rallybio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Rallybio \/ Not Applicable"},{"orgOrder":0,"company":"Rallybio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rallybio Announces Preliminary Multiple Dose Data from the Completed Phase 1 Safety and Pharmacokinetics Study for RLYB212, an Anti-HPA-1a Monoclonal Antibody for the Prevention of Fetal and Neonatal Alloimmune Thrombocytopenia","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"RLYB212","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Rallybio","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Rallybio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Rallybio \/ Not Applicable"},{"orgOrder":0,"company":"Rallybio","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","amount":"$6.6 million","upfrontCash":"Undisclosed","newsHeadline":"Rallybio Announces Collaboration to Advance Therapeutic Solutions for Pregnant Individuals at Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Collaboration","leadProduct":"RLYB212","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Rallybio","amount2":0.01,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Rallybio \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"6","companyTruncated":"Rallybio \/ Johnson & Johnson Innovative Medicine"}]
Find Clinical Drug Pipeline Developments & Deals by Rallybio
Details :
Under this collaboration, Johnson & Johnson will provide funding for Rallybio's RLYB212, the sole investigational therapy currently in clinical development aimed at addressing the needs of pregnant individuals at risk of FNAIT.
Details :
RLYB116 is a novel antibody mimetic fusion protein, long-acting C5 inhibitor. It is being evaluated in phase 1 clinical trials for patients with complement-mediated diseases.
Details :
RLYB212, an anti-HPA-1a monoclonal antibody and once monthly subcutaneous administration, being developed for the prevention of fetal and neonatal alloimmune thrombocytopenia.
Details :
RLYB212 to rapidly accelerate the elimination of HPA-1a positive platelets transfused to HPA-1a negative healthy male participants. It is being developed to prevent fetal and neonatal alloimmune thrombocytopenia.
Details :
RLYB211 is a polyclonal anti-HPA-1a antibody derived from human plasma, it is being investigated for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT).
Details :
RLYB212 to rapidly accelerate the elimination of HPA-1a positive platelets transfused to HPA-1a negative healthy male participants. It is being developed to prevent fetal and neonatal alloimmune thrombocytopenia.
Details :
The partnership will evaluate sustained delivery of Rallybio’s inhibitor of complement component 5 using EyePoint’s proprietary Durasert technology for sustained intraocular drug delivery. RLYB114 is a C5-targeted Affibody® molecule conjugated to po...
Details :
The results demonstrate that low doses of the two HPA-1a-specific antibodies, the polyclonal candidate RLYB211 and the monoclonal candidate RLYB212, are equally effective at rapidly clearing HPA-1a-positive platelets from circulation and preventing alloi...
Details :
Under the terms of the agreement, AbCellera and Rallybio will co-develop up to five rare disease novel antibody-based therapeutic targets, which will be chosen together by both companies.
Details :
Subcutaneously administered RLYB116 was observed to be generally well-tolerated at the 100 mg dose, with mild or moderate adverse events and no drug-related serious adverse events reported.
Market Place
Reset All
